Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Income from Continuing Operations (2016 - 2025)

Sonoma Pharmaceuticals has reported Income from Continuing Operations over the past 16 years, most recently at 819000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 11.75% year-over-year to 819000.0; the TTM value through Dec 2025 reached 3370000.0, up 10.09%, while the annual FY2025 figure was 3457000.0, 28.5% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 819000.0 at Sonoma Pharmaceuticals, down from 534000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 100000.0 in Q3 2021 and troughed at 3753000.0 in Q1 2022.
  • A 5-year average of 1272850.0 and a median of 1042000.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 917.0% in 2022 and later skyrocketed 65.15% in 2023.
  • Year by year, Income from Continuing Operations stood at 944000.0 in 2021, then crashed by 105.4% to 1939000.0 in 2022, then soared by 55.34% to 866000.0 in 2023, then dropped by 7.16% to 928000.0 in 2024, then grew by 11.75% to 819000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SNOA at 819000.0 in Q4 2025, 534000.0 in Q3 2025, and 1241000.0 in Q2 2025.